Osteosarcomas are malignant tumors of bone, most commonly seen in children and adolescents. Despite advances in modern medicine, the poor survival rate of metastatic osteosarcoma has not improved in two decades. In the present study we have investigated the effect of Riluzole on a human and mouse metastatic osteosarcoma cells. We show that LM7 cells secrete glutamate in the media and that mGluR5 receptors are required for the proliferation of LM7 cells. Riluzole, which is known to inhibit glutamate release, inhibits proliferation, induces apoptosis and prevents migration of LM7 cells. This is also seen with Fenobam, a specific blocker of mGluR5. We also show that Riluzole alters the phosphorylation status of AKT/P70 S6 kinase, ERK1/2 and JNK1/2. Thus Riluzole is an effective drug to inhibit proliferation and survival of osteosarcoma cells and has therapeutic potential for the treatment of osteosarcoma exhibiting autocrine glutamate signaling.
Liao, Sally; Ruiz, Yuleisy; Gulzar, Hira; Yelskaya, Zarina; Taouit, Lyes Ait; Houssou, Murielle; Jaikaran, Trisha; Schvarts, Yuriy; Kozlitina, Kristina; Basu-Roy, Upal; Mansukhani, Alka; and Mahajan, Shahana S., "Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole" (2017). CUNY Academic Works.